Standard

Успешное применение Цитофлавина у пациентки с постковидным синдромом. / Lemeshevskaia, O I; Kamaeva, E A; Lukashenko, M V; Gavrilova, N Yu; Soprun, L A.

In: ЖУРНАЛ НЕВРОЛОГИИ И ПСИХИАТРИИ ИМ. C.C. КОРСАКОВА, Vol. 123, No. 7, 2023, p. 108-111.

Research output: Contribution to journal › Article › peer-review

Harvard

Lemeshevskaia, OI, Kamaeva, EA, Lukashenko, MV, Gavrilova, NY & Soprun, LA 2023, 'Успешное применение Цитофлавина у пациентки с постковидным синдромом', ЖУРНАЛ НЕВРОЛОГИИ И ПСИХИАТРИИ ИМ. C.C. КОРСАКОВА, vol. 123, no. 7, pp. 108-111. https://doi.org/10.17116/jnevro2023123071108

APA

Lemeshevskaia, O. I., Kamaeva, E. A., Lukashenko, M. V., Gavrilova, N. Y., & Soprun, L. A. (2023). Успешное применение Цитофлавина у пациентки с постковидным синдромом. ЖУРНАЛ НЕВРОЛОГИИ И ПСИХИАТРИИ ИМ. C.C. КОРСАКОВА, 123(7), 108-111. https://doi.org/10.17116/jnevro2023123071108

Vancouver

Lemeshevskaia OI, Kamaeva EA, Lukashenko MV, Gavrilova NY, Soprun LA. Успешное применение Цитофлавина у пациентки с постковидным синдромом. ЖУРНАЛ НЕВРОЛОГИИ И ПСИХИАТРИИ ИМ. C.C. КОРСАКОВА. 2023;123(7):108-111. https://doi.org/10.17116/jnevro2023123071108

Author

Lemeshevskaia, O I ; Kamaeva, E A ; Lukashenko, M V ; Gavrilova, N Yu ; Soprun, L A. / Успешное применение Цитофлавина у пациентки с постковидным синдромом. In: ЖУРНАЛ НЕВРОЛОГИИ И ПСИХИАТРИИ ИМ. C.C. КОРСАКОВА. 2023 ; Vol. 123, No. 7. pp. 108-111.

BibTeX

@article{4d9077c5d8974ed5972c24e390a30c97,
title = "Успешное применение Цитофлавина у пациентки с постковидным синдромом",
abstract = "A clinical observation of the use of Cytoflavin according to a two-stage scheme (10.0 ml intravenously drip per 200 ml of 0.9% sodium chloride solution for 10 days, followed by a transition to a tablet form of 2 tablets 2 times/day for 25 days) in a patient with postcovid syndrome with pronounced vegetative and neurocognitive disorders. The effectiveness of therapy was confirmed by an improvement in heart rate variability and a decrease in the severity of depression, anxiety (on the HADS scale) and the level of autonomic dysfunction (on the COMPASS-31 scale). The significant changes in levels of fatigue (on a scale MFI) is not marked. The obtained results can serve as a basis for further research.",
keywords = "Humans, Niacinamide/therapeutic use, Flavin Mononucleotide/therapeutic use, Drug Combinations, Inosine Diphosphate/therapeutic use, Succinates/therapeutic use, COVID-19, Cytoflavin, dysautonomia, heart rate variability, neurocognitive disorders, postaveny syndrome, the new coronavirus infection",
author = "Lemeshevskaia, {O I} and Kamaeva, {E A} and Lukashenko, {M V} and Gavrilova, {N Yu} and Soprun, {L A}",
year = "2023",
doi = "10.17116/jnevro2023123071108",
language = "русский",
volume = "123",
pages = "108--111",
journal = "ЖУРНАЛ НЕВРОЛОГИИ И ПСИХИАТРИИ ИМ. C.C. КОРСАКОВА",
issn = "1997-7298",
publisher = "Медицина",
number = "7",

}

RIS

TY - JOUR

T1 - Успешное применение Цитофлавина у пациентки с постковидным синдромом

AU - Lemeshevskaia, O I

AU - Kamaeva, E A

AU - Lukashenko, M V

AU - Gavrilova, N Yu

AU - Soprun, L A

PY - 2023

Y1 - 2023

N2 - A clinical observation of the use of Cytoflavin according to a two-stage scheme (10.0 ml intravenously drip per 200 ml of 0.9% sodium chloride solution for 10 days, followed by a transition to a tablet form of 2 tablets 2 times/day for 25 days) in a patient with postcovid syndrome with pronounced vegetative and neurocognitive disorders. The effectiveness of therapy was confirmed by an improvement in heart rate variability and a decrease in the severity of depression, anxiety (on the HADS scale) and the level of autonomic dysfunction (on the COMPASS-31 scale). The significant changes in levels of fatigue (on a scale MFI) is not marked. The obtained results can serve as a basis for further research.

AB - A clinical observation of the use of Cytoflavin according to a two-stage scheme (10.0 ml intravenously drip per 200 ml of 0.9% sodium chloride solution for 10 days, followed by a transition to a tablet form of 2 tablets 2 times/day for 25 days) in a patient with postcovid syndrome with pronounced vegetative and neurocognitive disorders. The effectiveness of therapy was confirmed by an improvement in heart rate variability and a decrease in the severity of depression, anxiety (on the HADS scale) and the level of autonomic dysfunction (on the COMPASS-31 scale). The significant changes in levels of fatigue (on a scale MFI) is not marked. The obtained results can serve as a basis for further research.

KW - Humans

KW - Niacinamide/therapeutic use

KW - Flavin Mononucleotide/therapeutic use

KW - Drug Combinations

KW - Inosine Diphosphate/therapeutic use

KW - Succinates/therapeutic use

KW - COVID-19

KW - Cytoflavin

KW - dysautonomia

KW - heart rate variability

KW - neurocognitive disorders

KW - postaveny syndrome

KW - the new coronavirus infection

UR - https://www.mendeley.com/catalogue/edaed652-aace-3c76-81f0-69e1eb5bee6d/

U2 - 10.17116/jnevro2023123071108

DO - 10.17116/jnevro2023123071108

M3 - статья

C2 - 37490674

VL - 123

SP - 108

EP - 111

JO - ЖУРНАЛ НЕВРОЛОГИИ И ПСИХИАТРИИ ИМ. C.C. КОРСАКОВА

JF - ЖУРНАЛ НЕВРОЛОГИИ И ПСИХИАТРИИ ИМ. C.C. КОРСАКОВА

SN - 1997-7298

IS - 7

ER -

ID: 108470676